The heterogeneous population of cells obtained from processed adipose tissue, known as stromal vascular fraction (SVF), exhibits immunomodulatory and angiogenic properties. The therapeutic efficacy of SVF has been substantiated in numerous diseases, instilling hope for its clinical application as a cellular therapy. This study aims to provide a comprehensive analysis of the scholarly literature on SVF, including its worldwide progression, highlighting significant literatures, temporal development, research clusters, current active topics, and emerging trends. The combination of CiteSpace, HistCite Pro, and VOS Viewer tools was used to analyze the SVF literature. The overall panorama of the field is elucidated in terms of publication count, timeline, institutional distribution, journal coverage, and authors' contributions. In addition, this analysis explores the literature and keywords through the lens of co-occurrence, citation, and co-citation frequencies. Clustering algorithms are used to track the trajectory of the literature further, providing insight into its development. The findings offer a comprehensive overview of the progress made in the SVF field, highlighting distinct phases of development: the “Seedling period” from 1980 to 2010, the “Panicle period” from 2011 to 2016, and the “Flowering period” from 2017 to 2023. Within these periods, the evolution of 10 clusters is unraveled, encompassing topics such as vascular disease, CD34 expression, adipose tissue macrophage in 2013, cell-assisted lipotransfer, and knee osteoarthritis. In summary, this bibliometric study, conducting a quantitative analysis of publications in SVF research, encompasses a global overview of research, an analysis of pivotal literature in the field, research hotspots, and emerging frontiers.
Impact statement
This is the first bibliometric analysis conducted in the field of stromal vascular fraction (SVF) in the past 40 years. Unlike traditional reviews, this study used quantitative methods and tools to analyze and evaluate information from the literature related to SVF. The study revealed the associations, trends, and impact of research activities in the field of SVF.
Get full access to this article
View all access options for this article.
References
1.
ZukPA, ZhuM, AshjianP, et al.Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell, 2002; 13(12):4279–4295.
2.
SuzukiE, FujitaD, TakahashiM, et al.Adipose tissue-derived stem cells as a therapeutic tool for cardiovascular disease. World J Cardiol, 2015; 7(8):454–465.
3.
LockeM, WindsorJ, DunbarPR. Human adipose-derived stem cells: Isolation, characterization and applications in surgery. ANZ J Surg, 2009; 79(4):235–244.
4.
KemilewJ, Sobczyńska-RakA, ŻylińskaB, et al.The use of allogenic stromal vascular fraction (SVF) cells in degenerative joint disease of the spine in dogs. In Vivo, 2019; 33(4):1109–1117.
5.
StevensHP, DonnersS, de BruijnJ. Introducing platelet-rich stroma: Platelet-rich plasma (PRP) and stromal vascular fraction (SVF) combined for the treatment of androgenetic alopecia. Aesthet Surg J, 2018; 38(8):811–822.
6.
KimSJ, KimMJ, LeeYJ, et al.Innovative method of alopecia treatment by autologous adipose-derived SVF. Stem Cell Res Ther, 2021; 12(1):486.
7.
DaumasA, MagalonJ, JouveE, et al.Adipose tissue-derived stromal vascular fraction for treating hands of patients with systemic sclerosis: A multicentre randomized trial Autologous AD-SVF versus placebo in systemic sclerosis. Rheumatology (Oxford), 2022; 61(5):1936–1947.
8.
SunM, HeY, ZhouT, et al.Adipose extracellular matrix/stromal vascular fraction gel secretes angiogenic factors and enhances skin wound healing in a murine model. Biomed Res Int, 2017; 2017:3105780.
9.
SinghN. Scientometric analysis of research on Zika virus. Virusdisease, 2016; 27(3):303–306.
10.
DavarazarM, KamaliM, LopesI. Engineered nanomaterials for (waste)water treatment - A scientometric assessment and sustainability aspects. NanoImpact, 2021; 22(2021):100316.
11.
CaiW, YuLD, TangX, et al.The stromal vascular fraction improves maintenance of the fat graft volume: A systematic review. Ann Plast Surg, 2018; 81(2018):367–371.
12.
LiuJ, WangY, ZhangQ, et al.Scientometric analysis of public health emergencies: 1994–2020. Int J Environ Res Public Health, 2022; 19(2):640.
13.
ChenC. CiteSpace II: Detecting and visualizing emerging trends. J Am Soc Inform Sci Technol, 2006; 57(3):359–377.
14.
SweilehWM. Research trends on human trafficking: A bibliometric analysis using Scopus database. Global Health, 2018; 14(2018):106.
15.
PengC, KuangL, ZhaoJ, et al.Bibliometric and visualized analysis of ocular drug delivery from 2001 to 2020. J Control Release, 2022; 345(2022):625–645.
16.
TraktuevDO, Merfeld-ClaussS, LiJ, et al.A population of multipotent CD34-positive adipose stromal cells share pericyte and mesenchymal surface markers, reside in a periendothelial location, and stabilize endothelial networks. Circ Res, 2008; 102(1):77–85.
17.
PremaratneGU, MaLP, FujitaM, et al.Stromal vascular fraction transplantation as an alternative therapy for ischemic heart failure: Anti-inflammatory role. J Cardiothorac Surg, 2011; 6:43.
18.
JoCH, LeeYG, ShinWH, et al.Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: A proof-of-concept clinical trial. Stem Cells, 2014; 32(5):1254–1266.
19.
ZukPA, ZhuM, MizunoH, et al.Multilineage cells from human adipose tissue: Implications for cell-based therapies. Tissue Eng, 2001; 7(2):211–228.
20.
Planat-BenardV, SilvestreJS, CousinB, et al.Plasticity of human adipose lineage cells toward endothelial cells: Physiological and therapeutic perspectives. Circulation, 2004; 109(5):656–663.
21.
BourinP, BunnellBA, CasteillaL, et al.Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: A joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). Cytotherapy, 2013; 15(6):641–648.
22.
GentileP, ScioliMG, BielliA, et al.Comparing different nanofat procedures on scars: Role of the stromal vascular fraction and its clinical implications. Regen Med, 2017; 12(8):939–952.
23.
YaoY, DongZ, LiaoY, et al.Adipose extracellular matrix/stromal vascular fraction gel: A novel adipose tissue-derived injectable for stem cell therapy. Plast Reconstr Surg, 2017; 139(4):867–879.
24.
HongZ, ChenJ, ZhangS, et al.Intra-articular injection of autologous adipose-derived stromal vascular fractions for knee osteoarthritis: A double-blind randomized self-controlled trial. Int Orthop, 2019; 43(5):1123–1134.
25.
BoraP, MajumdarAS. Adipose tissue-derived stromal vascular fraction in regenerative medicine: A brief review on biology and translation. Stem Cell Res Ther, 2017; 8(1):145.
XiongS, LiuK, YangF, et al.Global research trends on inflammatory bowel diseases and colorectal cancer: A bibliometric and visualized study from 2012 to 2021. Front Oncol, 2022; 12(2022):943294.
28.
AlessiMC, PeirettiF, MorangeP, et al.Production of plasminogen activator inhibitor 1 by human adipose tissue: Possible link between visceral fat accumulation and vascular disease. Diabetes, 1997; 46(5):860–867.
29.
MiranvilleA, HeeschenC, SengenèsC, et al.Improvement of postnatal neovascularization by human adipose tissue-derived stem cells. Circulation, 2004; 110(3):349–355.
30.
RehmanJ, TraktuevD, LiJ, et al.Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation, 2004; 109(10):1292–1298.
31.
XuH, BarnesGT, YangQ, et al.Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest, 2003; 112(12):1821–1830.
32.
HotamisligilGS, ShargillNS, SpiegelmanBM. Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance. Science, 1993; 259(5091):87–91.
33.
CharrièreG, CousinB, ArnaudE, et al.Preadipocyte conversion to macrophage. Evidence of plasticity. J Biol Chem, 2003; 278(11):9850–9855.
34.
DingL, GuH, GaoX, et al.Aurora kinase a regulates m1 macrophage polarization and plays a role in experimental autoimmune encephalomyelitis. Inflammation, 2015; 38(2):800–811.
35.
MartinezFO, GordonS. The M1 and M2 paradigm of macrophage activation: Time for reassessment. F1000Prime Rep, 2014; 6(2014):13.
36.
BowlesAC, WiseRM, GersteinBY, et al.Immunomodulatory effects of adipose stromal vascular fraction cells promote alternative activation macrophages to repair tissue damage. Stem Cells, 2017; 35(10):2198–2207.
37.
KuroshimaS, SasakiM, NakajimaK, et al.Transplantation of noncultured stromal vascular fraction cells of adipose tissue ameliorates osteonecrosis of the jaw-like lesions in mice. J Bone Miner Res, 2018; 33(1):154–166.
38.
DongZ, FuR, LiuL, et al.Stromal vascular fraction (SVF) cells enhance long-term survival of autologous fat grafting through the facilitation of M2 macrophages. Cell Biol Int, 2013; 37(8):855–859.
39.
AnjikiK, MatsumotoT, KurodaY, et al.Heterogeneous cells as well as adipose-derived stromal cells in stromal vascular fraction contribute to enhance anabolic and inhibit catabolic factors in osteoarthritis. Stem Cell Rev Rep, 2023; 19(7):2407–2419.
40.
MatsumotoD, SatoK, GondaK, et al.Cell-assisted lipotransfer: Supportive use of human adipose-derived cells for soft tissue augmentation with lipoinjection. Tissue Eng, 2006; 2(12):3375–3382.
41.
TonnardP, VerpaeleA, PeetersG, et al.Nanofat grafting: Basic research and clinical applications. Plast Reconstr Surg, 2013; 132(4):1017–1026.
42.
WeiH, GuSX, LiangYD, et al.Nanofat-derived stem cells with platelet-rich fibrin improve facial contour remodeling and skin rejuvenation after autologous structural fat transplantation. Oncotarget, 2017; 8(40):68542–68556.
43.
LiangZJ, LuX, LiDQ, et al.Precise intradermal injection of nanofat-derived stromal cells combined with platelet-rich fibrin improves the efficacy of facial skin rejuvenation. Cell Physiol Biochem, 2018; 47(1):316–329.
44.
AmirkhaniMA, Shoae-HassaniA, SoleimaniM, et al.Rejuvenation of facial skin and improvement in the dermal architecture by transplantation of autologous stromal vascular fraction: A clinical study. Bioimpacts, 2016; 6(3):149–154.
45.
PakJ. Regeneration of human bones in hip osteonecrosis and human cartilage in knee osteoarthritis with autologous adipose-tissue-derived stem cells: A case series. J Med Case Rep, 2011; 5(2011):296.
46.
PakJ, LeeJH, PakN, et al.Cartilage regeneration in humans with adipose tissue-derived stem cells and adipose stromal vascular fraction cells: Updated status. Int J Mol Sci, 2018; 19(7):2146.
47.
GranelB, DaumasA, JouveE, et al.Safety, tolerability and potential efficacy of injection of autologous adipose-derived stromal vascular fraction in the fingers of patients with systemic sclerosis: An open-label phase I trial. Ann Rheum Dis, 2015; 74(12):2175–2182.
48.
CyranoskiD. Korean deaths spark inquiry. Nature, 2010; 468(7323):485.
49.
McLeanAK, StewartC, KerridgeI. Untested, unproven, and unethical: The promotion and provision of autologous stem cell therapies in Australia. Stem Cell Res Ther, 2015; 6(1):33.
50.
ToccoI, WidgerowAD, LalezariS, et al.Lipotransfer: The potential from bench to bedside. Ann Plast Surg, 2014; 72(5):599–609.
51.
YokotaN, HattoriM, OhtsuruT, et al.Comparative clinical outcomes after intra-articular injection with adipose-derived cultured stem cells or noncultured stromal vascular fraction for the treatment of knee osteoarthritis. Am J Sports Med, 2019; 47(11):2577–2583.
52.
ShanmugasundaramS, VaishA, ChavadaV, et al.Assessment of safety and efficacy of intra-articular injection of stromal vascular fraction for the treatment of knee osteoarthritis-a systematic review. Int Orthop, 2021; 45(3):615–625.
53.
TrivisonnoA, AlexanderRW, BaldariS, et al.Intraoperative strategies for minimal manipulation of autologous adipose tissue for cell- and tissue-based therapies: Concise review. Stem Cells Transl Med, 2019; 8(12):1265–1271.
54.
BalkoS, KerrE, BuchelE, et al.Paracrine signalling between keratinocytes and SVF cells results in a new secreted cytokine profile during wound closure. Stem Cell Res Ther, 2023; 14(1):258.
55.
RosaI, RomanoE, FiorettoBS, et al.Adipose-derived stem cells: Pathophysiologic implications vs therapeutic potential in systemic sclerosis. World J Stem Cells, 2021; 13(1):30–48.
56.
MehranfarS, Abdi RadI, MostafavE, et al.The use of stromal vascular fraction (SVF), platelet-rich plasma (PRP) and stem cells in the treatment of osteoarthritis: An overview of clinical trials. Artif Cells Nanomed Biotechnol, 2019; 47(1):882–890.
57.
JoshF, SoekamtoTH, AdrianiJR, et al.The combination of stromal vascular fraction cells and platelet-rich plasma reduces malondialdehyde and nitric oxide levels in deep dermal burn injury. J Inflamm Res, 2021; 14(2021):3049–3061.
58.
PriglingerE, StrohmeierK, WeiglM, et al.SVF-derived extracellular vesicles carry characteristic miRNAs in lipedema. Sci Rep, 2020; 10(1):7211.
59.
LvX, HeJ, ZhangX, et al.Comparative efficacy of autologous stromal vascular fraction and autologous adipose-derived mesenchymal stem cells combined with hyaluronic acid for the treatment of sheep osteoarthritis. Cell Transplant, 2018; 27(7):1111–1125.
60.
ParkSS, ParkM, LeeBT. Autologous stromal vascular fraction-loaded hyaluronic acid/gelatin-biphasic calcium phosphate scaffold for bone tissue regeneration. Mater Sci Eng C Mater Biol Appl, 2022; 132(2022):112533.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
